Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DMOV12
|
|||
| Drug Name |
Tominersen
|
|||
| Indication | Huntington disease [ICD-11: 8A01.10; ICD-10: G10; ICD-9: 294.1, 333.4] | Phase 3 | [1] | |
| Company |
Ionis
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Huntingtin (HTT) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03761849) A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease. U.S.National Institutes of Health. | |||
| REF 2 | Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities. Lancet Neurol. 2022 Jul;21(7):645-658. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.